GT Biopharma Inc (GTBP) — Cash Flow-to-Debt Ratio
GT Biopharma Inc (GTBP) has a Cash Flow-to-Debt Ratio of -1.02x as of March 2026, meaning its operating cash flow of $-2.47 Million could theoretically repay -1% of its total liabilities ($2.42 Million) in one year. See GTBP free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
GT Biopharma Inc Cash Flow-to-Debt Ratio (1985–2025)
Historical debt coverage capacity for GT Biopharma Inc across 41 annual periods. For the full cash flow conversion analysis, see GT Biopharma Inc cash flow conversion.
Annual Cash Flow-to-Debt Ratio for GT Biopharma Inc (1985–2025)
Year-by-year debt coverage analysis for GT Biopharma Inc. Check GT Biopharma Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -5.57x | $-12.91 Million | $2.32 Million | ▼ -154.7% |
| 2024 | -2.19x | $-12.90 Million | $5.90 Million | ▼ -63.8% |
| 2023 | -1.33x | $-8.85 Million | $6.63 Million | ▲ +56.1% |
| 2022 | -3.04x | $-15.22 Million | $5.00 Million | ▼ -100.0% |
| 2021 | -1.52x | $-15.61 Million | $10.26 Million | ▼ -635.1% |
| 2020 | -0.21x | $-7.26 Million | $35.09 Million | ▼ -11.4% |
| 2019 | -0.19x | $-3.66 Million | $19.71 Million | ▲ +75.6% |
| 2018 | -0.76x | $-10.68 Million | $14.03 Million | ▲ +62.5% |
| 2017 | -2.03x | $-5.43 Million | $2.68 Million | ▼ -1890.0% |
| 2016 | -0.10x | $-1.93 Million | $18.95 Million | ▼ -10.7% |
| 2015 | -0.09x | $-4.66 Million | $50.62 Million | ▼ -60.2% |
| 2014 | -0.06x | $-1.75 Million | $30.46 Million | ▲ +15.8% |
| 2013 | -0.07x | $-442.00K | $6.48 Million | ▲ +54.7% |
| 2012 | -0.15x | $-987.00K | $6.56 Million | ▲ +18.3% |
| 2011 | -0.18x | $-963.00K | $5.23 Million | ▲ +32.2% |
| 2010 | -0.27x | $-1.53 Million | $5.65 Million | ▼ -105.9% |
| 2009 | -0.13x | $-937.00K | $7.11 Million | ▼ -233.1% |
| 2008 | -0.04x | $-169.00K | $4.27 Million | ▲ +52.7% |
| 2007 | -0.08x | $-270.00K | $3.23 Million | ▲ +2.7% |
| 2006 | -0.09x | $-671.00K | $7.80 Million | ▲ +82.5% |
| 2005 | -0.49x | $-2.09 Million | $4.27 Million | ▼ -26.1% |
| 2004 | -0.39x | $-1.04 Million | $2.68 Million | ▼ -85.6% |
| 2003 | -0.21x | $-229.00K | $1.09 Million | ▲ +84.1% |
| 2002 | -1.31x | $-1.01 Million | $767.00K | ▼ -9.6% |
| 2001 | -1.20x | $-1.43 Million | $1.19 Million | ▲ +52.1% |
| 2000 | -2.50x | $-3.89 Million | $1.55 Million | ▼ -152.3% |
| 1999 | -0.99x | $-2.48 Million | $2.50 Million | ▲ +23.6% |
| 1998 | -1.30x | $-5.20 Million | $4.00 Million | ▼ -57.1% |
| 1997 | -0.83x | $-4.80 Million | $5.80 Million | ▲ +32.6% |
| 1996 | -1.23x | $-4.30 Million | $3.50 Million | ▼ -29.8% |
| 1995 | -0.95x | $-5.30 Million | $5.60 Million | ▼ -1164.7% |
| 1994 | 0.09x | $400.00K | $4.50 Million | ▲ +101.7% |
| 1993 | -5.33x | $-1.60 Million | $300.00K | ▼ -540.0% |
| 1992 | -0.83x | $-500.00K | $600.00K | ▲ +16.7% |
| 1991 | -1.00x | $-200.00K | $200.00K | ▼ -122.2% |
| 1990 | 4.50x | $900.00K | $200.00K | ▲ +221.4% |
| 1989 | 1.40x | $700.00K | $500.00K | ▲ +320.0% |
| 1988 | 0.33x | $100.00K | $300.00K | ▲ +33.3% |
| 1987 | 0.25x | $50.00K | $200.00K | ▲ +131.3% |
| 1986 | -0.80x | $-400.00K | $500.00K | ▲ +73.3% |
| 1985 | -3.00x | $-300.00K | $100.00K | — |